SCHEMBL6480965

SCHEMBL6480965

CC(CNS(=O)(=O)C(C)C)Oc1ccc(-c2ccccc2Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 12/20 0.48
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
GRIA1 P42261 1/20 0.36
GRIA2 P42262 1/20 0.36
GRIA3 P42263 1/20 0.36
NR1D1 P20393 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2A6 P11509 1/20 0.36
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35
PRKAB1 Q9Y478 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480938 0.86 GRIA4 (0.49) GRIA4MTNR1AMTNR1BGRIA1GRIA2
SCHEMBL6473885 0.85 GRIA4 (0.67) GRIA4MTNR1AMTNR1BGRIA1GRIA2
SCHEMBL6480970 0.84 GRIA4 (0.51) GRIA4MTNR1AMTNR1BNR1D1ALDH1A1
SCHEMBL6475291 0.84 GRIA4 (0.62) GRIA4MTNR1AMTNR1BGRIA1GRIA2
SCHEMBL6482318 0.84 GRIA4 (0.53) GRIA4MTNR1AMTNR1BGRIA1GRIA2
SCHEMBL6481760 0.83 GRIA4 (0.46) GRIA4MTNR1AMTNR1BGRIA1GRIA2
SCHEMBL6472657 0.83 GRIA4 (0.47) GRIA4MTNR1AMTNR1BGRIA1GRIA2
SCHEMBL6480921 0.82 PPARG (0.48) GRIA4MTNR1AMTNR1BNR1D1
SCHEMBL6474261 0.79 GRIA4 (0.47) GRIA4GRIA1GRIA2GRIA3ALDH1A1
SCHEMBL6482156 0.79 MTNR1A (0.52) GRIA4MTNR1AMTNR1BGRIA1GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885MTNR1A 443/4885MTNR1B 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.